The company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue.
Developed at the University of Utah, this is the first in the ChondroMatch line of instrumentation for osteochondral allograft repair in the knee and ankle to enter clinical use.
Carlsmed’s personalized spine platform combines AI-driven preoperative planning with 3D-printed, patient-specific implants tailored to each patient’s anatomy and pathology.
The SImmetry+ lateral access solution incorporates established fusion principles, including joint decortication, bone graft placement, and rigid fixation, to achieve true biological fusion across the SI joint.